TP63 and squamous cell lung carcinoma: Exosomal TP63, KRT5, CEACAM6, and SFTPB mRNAs can be used as biomarkers to differentiate between lung squamous cell carcinoma (LUSC) and lung squamous cell carcinoma (LUAD), thereby, providing a novel strategy for their differential diagnosis and treatment [19].